Prelude Therapeutics (PRLD) Current Leases (2019 - 2026)

Prelude Therapeutics (PRLD) has 7 years of Current Leases data on file, last reported at $2.8 million in Q1 2026.

• For the quarter ending Q1 2026, Current Leases rose 6.19% year-over-year to $2.8 million; the trailing twelve-month figure through Mar 2026 stood at $2.8 million (up 6.19% YoY), and the FY2025 full-year result was $2.7 million, up 1219.23% from the prior year.
• Current Leases rose to $2.8 million in Q1 2026, from $2.7 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $2.8 million in Q1 2026 to a low of $208000.0 in Q4 2024.
• A 5-year average of $1.8 million and a median of $1.8 million in 2022 frame the typical range for Current Leases.
• Across the five-year window, Current Leases tumbled 85.96% in 2024 and soared 1219.23% in 2025, its largest moves.
• Tracing PRLD's Current Leases over 5 years: stood at $1.8 million in 2022, then fell by 19.16% to $1.5 million in 2023, then plunged by 85.96% to $208000.0 in 2024, then soared by 1219.23% to $2.7 million in 2025, then rose by 0.62% to $2.8 million in 2026.
• Business Quant data shows PRLD's Current Leases at $2.8 million in Q1 2026, $2.7 million in Q4 2025, and $2.7 million in Q3 2025.